Royalty Pharma PLC (NAS:RPRX)
$ 28.09 0.12 (0.43%) Market Cap: 12.67 Bil Enterprise Value: 17.27 Bil PE Ratio: 15.87 PB Ratio: 1.95 GF Score: 79/100

Royalty Pharma PLC at Cowen Health Care Conference (Virtual) Transcript

Mar 08, 2022 / 04:10PM GMT
Release Date Price: $37.67 (-0.84%)
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Well, good morning, and welcome to the Royalty Pharma session at Cowen's 42nd Annual Health Care Conference. We're very pleased to have top management of Royalty Pharma here with us again this year. Representing the company is Marshall Urist, who is Executive Vice President and Co-head Research and [Investments] (corrected by company after the call) as well as joining us for Q&A, Terry Coyne, who is Executive Vice President and CFO.

Before I turn it to Marshall to show a few introductory slides, I just would like to note that we at Cowen view Royalty Pharma, as one of the most differentiated companies in biopharma given the fact that it is positioned to enjoy the promise of innovation, but we do believe with less risk. So interesting situation and to learn more about that, I will turn it to Marshall.

Marshall Urist
Royalty Pharma plc - Executive VP and Co-Head of Research & Investments

Thanks, Steve, and good morning to everyone. So we are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot